# Hepa Thera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hepa-thera

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.hepathera.com/
- Total disclosed funding: $98M
- Latest round: Series B (May 29, 2026)
- Investors on record: 8

## About

Based in Suzhou, China, and founded in 2021, Suzhou HepaThera Biotech Co., Ltd. provides therapeutic treatments for the biopharmaceutical sector. The CEO of the company, Yanqin Ma, was the vice president of Jiangsu Enhua Pharmaceutical Research Institute, and the CMO, Shanzhong Zhang, worked at Shanghai First People's Hospital. In May 2026, the firm raised over CNY 630 million in series B funding.

The company works with research institutions and medical networks to provide liver disease treatments through a combination of proprietary research and licensed assets. Its core pipeline includes the HT-101 small interfering RNA injection and the HT-102 neutralizing antibody, which are utilized as a combination therapy to treat chronic hepatitis B.

The company generates revenue from business-to-business contracts through the licensing, collaborative development, and commercialization of its therapeutic drug pipelines and pipeline assets.

The company plans to use the Series B funding to advance the global clinical development and registration filing of its core products, expand combination therapy strategies, build commercialization and industrialization capabilities, and strengthen capital market planning.

## Funding rounds

- Series B, May 29, 2026, $93M — Kaitai Capital, Shanghai Fosun Pharmaceutical (Group), Tahoe VC, Huajin Lingchuang Fund Management, Hangzhou Qianhe Private Equity Fund Management, Deshi Capital, TG Sino-Dragon
- Seed, Jul 28, 2021, $4.6M — Fosun Health Capital

## Investors

- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Seed
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series B
- Shanghai Fosun Pharmaceutical (Group) — Series B
- Tahoe VC — Series B
- Huajin Lingchuang Fund Management (https://capitalatlas.ai/funds/huajin-lingchuang-fund-management) — Series B
- Hangzhou Qianhe Private Equity Fund Management (https://capitalatlas.ai/funds/hangzhou-qianhe-private-equity-fund-management) — Series B
- Deshi Capital (https://capitalatlas.ai/funds/deshi-capital) — Series B
- TG Sino-Dragon — Series B